[99mTc]Tc-iPSMA SPECT/CT as an alternative to PET imaging for decision making in prostate cancer patients. PREP registry: Key findings. Total (n=4135) Cohort 1 (n=255): BF within 3 months from RP and ...

Initial report of a randomized trial of post-prostatectomy prostate cancer radiotherapy using either fluciclovine (18F) or PSMA (68Ga) PET/CT for target dose-escalation. This is an ASCO Meeting ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Glenn Bauman discussing a prospective provincial registry of PSMA PET/CT for recurrent prostate cancer. While most ...

Radium-223 is an alpha-emitting radiopharmaceutical that accumulates in areas of high bone turnover and has demonstrated a survival benefit in metastatic prostate cancer, 1 but its benefits as a ...

Telix is in a strong financial position with net cash of AUD 140 million as of December 2024. We forecast free cash flow averaging 87% of net income over the next 10 years, and in the absence of major ...

PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.

The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.

Patients with pelvic imaging prior to enrollment who exhibited evidence of nodal or distant metastasis, had received bone scan or PSMA PET/CU prior to enrollment, had started prostate cancer treatment ...

For those unlucky enough to have received a testicular castration to treat prostate cancer, only for it to come back, Clarity ...

The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...